Support and Resistance Levels
Past performance
About Amanta Healthcare Ltd Amanta Healthcare Limited, established in 1994 and headquartered in Gujarat, India, is a pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid products using advanced technologies like Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company produces a broad range of large volume parenterals (LVPs) and small volume parenterals (SVPs) spanning six therapeutic segments, along with medical devices and closure systems. Its product portfolio includes IV fluids, formulations, diluents, ophthalmic, respiratory, and irrigation solutions, as well as eye lubricants, first-aid solutions, and innovative closure systems with container capacities from 2ml to 1000ml.
Amanta has progressively expanded its manufacturing capabilities, launching LVP production in 1998, followed by specialized production lines for SVPs and larger capacity LVPs between 2002 and 2008, all located in Gujarat. Its 2018 merger with Marck Remedies Private Limited, facilitated through a National Company Law Tribunal-approved scheme, integrated MRPL's business operations, further expanding Amanta's capabilities. The company now operates seven active production lines as of 2024, exemplifying consistent growth and innovation in sterile liquid manufacturing.
The company’s technological prowess and scalable infrastructure position it as a key player in pharmaceutical manufacturing, particularly in fluid therapy and sterile products. With its announcement of an Initial Public Offering (IPO) of up to 1.25 crore equity shares, Amanta seeks to leverage public investments to fuel further growth and enhance its production and market reach. This aligns with its vision of strengthening its foothold in both domestic and international markets.
The company’s robust history of innovation, strategic mergers, and product diversification make it an attractive consideration for traders eyeing growth-driven pharmaceutical investments.